Sumitomo Chemical India Ltd
Sumitomo Chemical India Ltd. (SCIL) is one of the leading players in the industry which has a balanced portfolio of technical as well as formulation products along with backward integration for some products. The Company is known for domestic marketing of proprietary products of its Japanese parent -Sumitomo Chemical Company Limited in agrochemicals, animal nutrition, and environmental health business segments. With the integration of Excel Crop Care Limited, the Company now has a strong portfolio of generics in addition to specialty products and a strong combined marketing network. With this integration, the Company has moved up several notches in the pecking order of the Indian crop protection industry. SCIL has also marked its presence in Africa and several other geographies of the world.[1] [2]
- Market Cap ₹ 20,844 Cr.
- Current Price ₹ 418
- High / Low ₹ 573 / 363
- Stock P/E 36.5
- Book Value ₹ 67.9
- Dividend Yield 0.31 %
- ROCE 22.1 %
- ROE 16.2 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 34.5%
Cons
- The company has delivered a poor sales growth of 4.13% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1,913 | 2,228 | 2,425 | 2,645 | 3,061 | 3,511 | 2,844 | 3,149 | 3,238 | 3,245 | |
| 1,693 | 1,938 | 2,090 | 2,157 | 2,459 | 2,844 | 2,369 | 2,516 | 2,567 | 2,560 | |
| Operating Profit | 220 | 291 | 335 | 488 | 602 | 667 | 475 | 633 | 671 | 685 |
| OPM % | 11% | 13% | 14% | 18% | 20% | 19% | 17% | 20% | 21% | 21% |
| 30 | 1 | -20 | 19 | 27 | 45 | 96 | 120 | 131 | 166 | |
| Interest | 5 | 4 | 7 | 7 | 8 | 6 | 6 | 7 | 8 | 8 |
| Depreciation | 24 | 28 | 41 | 47 | 45 | 52 | 62 | 66 | 66 | 68 |
| Profit before tax | 221 | 260 | 267 | 453 | 576 | 654 | 503 | 680 | 728 | 775 |
| Tax % | 34% | 36% | 23% | 24% | 26% | 23% | 26% | 26% | 25% | |
| 145 | 166 | 205 | 345 | 424 | 502 | 370 | 506 | 543 | 579 | |
| EPS in Rs | 4.10 | 6.92 | 8.49 | 10.06 | 7.40 | 10.13 | 10.88 | 11.61 | ||
| Dividend Payout % | 0% | 38% | 18% | 12% | 12% | 12% | 80% | 12% | 12% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | -3% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 2% |
| TTM: | 3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 0% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 16% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 275 | 275 | 499 | 499 | 499 | 499 | 499 | 499 | 499 |
| Reserves | 679 | 774 | 723 | 1,042 | 1,428 | 1,883 | 1,942 | 2,402 | 2,891 |
| 10 | 20 | 36 | 33 | 38 | 34 | 30 | 52 | 63 | |
| 694 | 792 | 849 | 1,098 | 1,045 | 953 | 841 | 1,010 | 1,021 | |
| Total Liabilities | 1,658 | 1,860 | 2,106 | 2,672 | 3,010 | 3,369 | 3,313 | 3,963 | 4,474 |
| 267 | 279 | 319 | 309 | 390 | 430 | 563 | 556 | 577 | |
| CWIP | 9 | 8 | 10 | 14 | 35 | 71 | 23 | 28 | 20 |
| Investments | 0 | 0 | 86 | 290 | 356 | 239 | 346 | 524 | 1,153 |
| 1,383 | 1,572 | 1,690 | 2,058 | 2,228 | 2,629 | 2,381 | 2,854 | 2,725 | |
| Total Assets | 1,658 | 1,860 | 2,106 | 2,672 | 3,010 | 3,369 | 3,313 | 3,963 | 4,474 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| 47 | 78 | 221 | 425 | 222 | 389 | 757 | 452 | 446 | |
| -40 | -35 | -118 | -283 | -290 | -327 | -420 | -392 | -332 | |
| 7 | -65 | -61 | -47 | -63 | -73 | -337 | -68 | -83 | |
| Net Cash Flow | 15 | -23 | 42 | 96 | -131 | -10 | -0 | -8 | 31 |
| Free Cash Flow | 4 | 39 | 184 | 383 | 109 | 270 | 695 | 423 | 403 |
| CFO/OP | 59% | 57% | 90% | 109% | 61% | 84% | 187% | 97% | 91% |
Ratios
Consolidated / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 105 | 110 | 128 | 117 | 101 | 98 | 92 | 91 | 83 |
| Inventory Days | 203 | 193 | 146 | 185 | 198 | 157 | 136 | 153 | 166 |
| Days Payable | 176 | 136 | 122 | 145 | 109 | 86 | 96 | 106 | 86 |
| Cash Conversion Cycle | 133 | 166 | 152 | 157 | 189 | 169 | 132 | 137 | 163 |
| Working Capital Days | 114 | 116 | 109 | 95 | 127 | 136 | 172 | 180 | 154 |
| ROCE % | 27% | 26% | 32% | 33% | 29% | 20% | 25% | 22% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Branded Products Revenue Share % |
|
||||||
| Domestic Revenue Share % |
|||||||
| Herbicides Revenue Share % |
|||||||
| Insecticides Revenue Share % |
|||||||
| Number of Distributors count |
|||||||
| Speciality Products Revenue Share % |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Intimation Of Schedule Of Board Meeting To Be Held On 26Th October, 2026.
- Board meeting on 26 October 2026 to consider Q2 and half-year FY2026 unaudited results.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Investor/analyst meetings with Elara Capital on 3 September 2026 in Mumbai.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Company will meet investors on 19 August 2026 at 3:00 pm in Mumbai, hosted by Motilal Oswal.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- AGM on 27 July 2026 approved ₹1.30 dividend and MD change effective 1 September 2026.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Investor Presentation on the financial results of the Company for the quarter ended 30th June, 2026
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
Concalls
-
Jul 2026PPT
-
Jun 2026Transcript PPT
-
Jan 2026PPT
-
Jan 2026PPT
-
Nov 2025Transcript PPT REC
-
Aug 2025PPT
-
Jun 2025Transcript PPT
-
Jan 2025PPT
-
Nov 2024Transcript PPT
-
Jul 2024PPT
-
Jun 2024Transcript PPT
-
Feb 2024PPT
-
Nov 2023Transcript PPT
-
Aug 2023PPT
-
May 2023Transcript PPT
-
Feb 2023PPT
-
Nov 2022Transcript PPT
-
Aug 2022PPT
-
Aug 2022PPT
-
Jun 2022Transcript PPT REC
-
Feb 2022PPT
-
Nov 2021Transcript PPT
-
Aug 2021PPT
-
Jun 2021Transcript PPT
-
Feb 2021PPT
-
Nov 2020Transcript PPT
-
Aug 2020PPT
-
Jun 2020PPT
-
Feb 2020PPT
Products
The company operates in agorchemicals, including insecticides, weedicides, fungicides, fumigants, rodenticides, plant growth nutrition products, bio-rationals, and plant growth regulators. It markets proprietary products from its Japanese parent, Sumitomo Chemical Co., in agrochemicals, animal nutrition, and environmental health.[1]
The products comprise conventional chemistry sourced from SCC, and biological products sourced from a USA-based subsidiary, Valent Biosciences LLC. [2]